Michael Avaricio, MD
Cardiology · Ozone Park, NYNPI 1639275084
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.3%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 43 manufacturers reported payments, led by Boehringer Ingelheim at 38.3% of the total. Reporting peaked in 2019 at $15,261 and has fallen 90.0% since, to $1,525 in 2025. Among cardiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 700 payments — averaging $58.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$16K
- Lilly USA, LLC$7K
- Merck$4K
- Johnson & Johnson$3K
- AstraZeneca$2K
- Boston Scientific$1K
- plus $8K from 37 others
Across 4 payments — averaging $1310.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cvrx, Inc.$5K
What the payments were for
- Consulting fees$3,7509%
- Speaking & faculty fees$16,83341%
- Travel & lodging$3,3398%
- Food & beverage$16,88441%
- Education$1020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,907 in reported general payments places this provider in the 95th percentile of 112 cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 294 | $313,321 |
| XareltoRivaroxaban | 252 | $266,432 |
| JardianceEmpagliflozin | 156 | $173,653 |
| OpsumitMacitentan | 13 | $166,709 |
| FarxigaDapagliflozin Propanediol | 143 | $146,878 |
| JanuviaSitagliptin Phosphate | 122 | $111,970 |
| EntrestoSacubitril/Valsartan | 77 | $104,245 |
| KerendiaFinerenone | 107 | $102,148 |
| OzempicSemaglutide | 79 | $79,824 |
| LinzessLinaclotide | 91 | $59,369 |
| Clemastine Fumarate | 15 | $41,027 |
| JanumetSitagliptin Phos/Metformin Hcl | 48 | $40,552 |
| TrulicityDulaglutide | 13 | $24,874 |
| VerquvoVericiguat | 20 | $23,404 |
| BrilintaTicagrelor | 23 | $23,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $392 | $313,321294 claims |
| Johnson & JohnsonXarelto | $2,822 | $266,432252 claims |
| Boehringer IngelheimJardiance, Tradjenta | $15,650 | $186,995167 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $2,161 | $179,474193 claims |
| MerckJanuvia, Janumet, Verquvo | $3,841 | $175,926190 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $889 | $166,70913 claims |
| NovartisEntresto | $531 | $104,24577 claims |
| BayerKerendia | $917 | $102,148107 claims |
| AbbVieLinzess | $49 | $59,36991 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $6,983 | $37,56525 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $191 | $12,81932 claims |
| GSKTrelegy Ellipta | $105 | $9,41515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 112 cardiology providers in New York.
Other cardiology in Ozone Park
- Felix OviasuGarden City$150K
- David D'agateSmithtown$69K
- Michael SiegalNew York$43K
- Bimalkumar BrahmbhattAmityville$31K
- Michael HappesSmithtown$30K
- Meyer AbittanRoslyn$28K
- Perminder GrewalStony Point$19K
- Paul SapiaRoslyn$19K
- Salim BaghdadiKew Gardens$18K
- Ralph CaselnovaAmityville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.